Skip to content
TheChatArchiveThe Chat Archive
Perplexitysonar· PerplexityHugging Face LMArena Search Arena 24K

Cisplatin treatment itself sometimes induces the activation of NF-κB in ovarian cancer…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Perplexitysonar-reasoning’s answer.
  1. User

    Cisplatin treatment itself sometimes induces the activation of NF-κB in ovarian cancer cells

  2. Perplexity Assistant

    Cisplatin treatment itself can induce the activation of the NF-κB signaling pathway in ovarian cancer cells, which is closely linked to chemoresistance and poor prognosis. Several studies have demonstrated that cisplatin-resistant ovarian cancer cells often show increased NF-κB activity, particularly the nuclear translocation and overexpression of the NF-κB p65 subunit. This activation promotes survival pathways that inhibit apoptosis, thereby reducing the effectiveness of cisplatin chemotherapy.

    Key points supporting this include:

    • NF-κB activation by cisplatin: Cisplatin can upregulate NF-κB activity through DNA damage response mechanisms, such as ATM-mediated phosphorylation of NF-κB inhibitors (IKKα and IKKβ), leading to NF-κB nuclear translocation and transcriptional activation of target genes that promote cell survival and chemoresistance[7].

    • Role in chemoresistance: Overexpression of NF-κB p65 is associated with advanced ovarian cancer stages, platinum resistance, and refractory disease. Blocking NF-κB activation with inhibitors (e.g., PDTC or SN50) enhances cisplatin sensitivity and increases apoptosis in resistant ovarian cancer cell lines like C13* and A2780cp[1][8].

    • Molecular mechanisms: NF-κB promotes the expression of anti-apoptotic genes such as BCL2 family members (BCL-XL, BCL2A1), inhibitors of apoptosis proteins (IAPs like XIAP, cIAP1/2), and other survival factors. This transcriptional program helps cancer cells evade cisplatin-induced apoptosis[7].

    • Biphasic role: NF-κB may have complex roles depending on the context; in some ovarian cancer models, it can act as a tumor suppressor, while in aggressive, chemoresistant variants, it functions as an oncogene promoting survival and resistance[2].

    • Additional factors: Proteins like p62/SQSTM1 can mediate cisplatin-induced NF-κB activation, further contributing to drug resistance by enhancing NF-κB signaling and inhibiting apoptosis[5].

    In summary, cisplatin treatment can paradoxically activate NF-κB in ovarian cancer cells, which then drives chemoresistance by upregulating anti-apoptotic and survival pathways. Targeting NF-κB signaling has been shown to improve cisplatin efficacy, suggesting that NF-κB activation is a critical mechanism of cisplatin resistance in ovarian cancer[1][7][8].

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.